Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Bone density in proton pump inhibitors users: a prospective study.

Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, Erer B, Sokmen MH.

Rheumatol Int. 2013 Sep;33(9):2255-60. doi: 10.1007/s00296-013-2709-0. Epub 2013 Mar 2.

PMID:
23455632
2.

Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.

Bahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, Thaçi K, Thaçi S, Karakulak Ç.

J Bone Miner Metab. 2015 Jul 25. [Epub ahead of print]

PMID:
26209167
3.

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W; CaMos Research Group.

Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10. Erratum in: Am J Gastroenterol. 2013 Jan;108(1):157.

PMID:
22777336
4.

Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.

Vasiliadis KV, Viazis N, Vlachogiannakos J, Sgouros SN, Stefanidis G, Archimandritis A, Karamanolis DG.

Am J Gastroenterol. 2010 Feb;105(2):308-13. doi: 10.1038/ajg.2009.556. Epub 2009 Oct 6.

PMID:
19809412
5.

Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients.

Kirkpantur A, Altun B, Arici M, Turgan C.

Int J Clin Pract. 2009 Feb;63(2):261-8. doi: 10.1111/j.1742-1241.2008.01883.x.

PMID:
19196364
6.

Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.

Higginbotham TW.

Ann Pharmacother. 2010 Mar;44(3):572-6. doi: 10.1345/aph.1M519. Epub 2010 Feb 2. Review.

PMID:
20124466
7.

The innovative potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to restore the "gastric barrier effect" in patients chronically treated with PPI: a pilot study.

Del Piano M, Anderloni A, Balzarini M, Ballarè M, Carmagnola S, Montino F, Orsello M, Pagliarulo M, Tari R, Soattini L, Sforza F, Mogna L, Mogna G.

J Clin Gastroenterol. 2012 Oct;46 Suppl:S18-26. doi: 10.1097/MCG.0b013e318267b55d.

PMID:
22955351
8.

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

Roux C, Goldstein JL, Zhou X, Klemes A, Lindsay R.

Osteoporos Int. 2012 Jan;23(1):277-84. doi: 10.1007/s00198-011-1574-5. Epub 2011 Mar 2.

PMID:
21365461
9.

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

Targownik LE, Lix LM, Leung S, Leslie WD.

Gastroenterology. 2010 Mar;138(3):896-904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.

PMID:
19931262
11.

Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.

Hoogendoorn RJ, Groeneveld L, Kwee JA.

Clin Drug Investig. 2009;29(12):803-10. doi: 10.2165/11530810-000000000-00000.

PMID:
19888786
12.

Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.

Clayton SB, Rife CC, Singh ER, Kalbfleisch JH, Castell DO.

Dis Esophagus. 2012 Nov-Dec;25(8):682-6. doi: 10.1111/j.1442-2050.2011.01310.x. Epub 2012 Jan 31.

PMID:
22292567
13.

Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.

Jonasson C, Tvete IF, Hatlebakk JG.

Scand J Gastroenterol. 2013 Sep;48(9):1010-7. doi: 10.3109/00365521.2013.812140. Epub 2013 Jul 16.

PMID:
23859491
14.

Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.

Hall J, Dodd S, Durkin M, Sloan S.

Manag Care. 2002 Jul;11(7 Suppl):14-8.

15.

Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.

Tjon JA, Pe M, Soscia J, Mahant S.

Pharmacotherapy. 2013 Sep;33(9):956-71. doi: 10.1002/phar.1299. Epub 2013 May 26. Review.

PMID:
23712734
16.

Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?

Eslami L, Nasseri-Moghaddam S.

Arch Iran Med. 2013 Aug;16(8):449-58. doi: 0013168/AIM.004.

17.

Fracture risk and bone mineral density reduction associated with proton pump inhibitors.

Lau YT, Ahmed NN.

Pharmacotherapy. 2012 Jan;32(1):67-79. doi: 10.1002/PHAR.1007. Review.

PMID:
22392829
18.

Effects of 99mTc-MIBI and 99mTc-MDP administration on dual-energy X-ray absorptiometry bone mineral density measurements.

Gumuser G, Parlak Y, Topal G, Aras F, Ruksen E, Sayit E.

Nucl Med Commun. 2009 Jun;30(6):445-8. doi: 10.1097/MNM.0b013e328329fc4c.

PMID:
19357550
19.

[The risks of long-term proton pump inhibitors use].

Jiang X, Zhang Q, Zhang Z, Liu Y.

Zhonghua Yi Xue Za Zhi. 2014 Jan 28;94(4):284-8. Chinese.

PMID:
24731496
20.

Proton pump inhibitor therapy and potential long-term harm.

Corleto VD, Festa S, Di Giulio E, Annibale B.

Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):3-8. doi: 10.1097/MED.0000000000000031. Review.

PMID:
24310148
Items per page

Supplemental Content

Write to the Help Desk